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Our understanding of the Rh blood group system
has been greatly advanced since the genes were cloned
in the late 1990s. We have witnessed the explosion of
information about the Rh blood group antigens with
the development of PCR and the rapid elucidation of
the genetic basis for the antigens and phenotypes. This
new genetic information explains some of the
longstanding questions about the Rh system, especially
the D antigen, leading to reemergence of discussions
about appropriate D testing approaches.
Serologic Foundation of Rh
Recent genetic information has confirmed many of
the predictions of the serologists whose primary, and
often only, tools were the antibodies made by
immunized individuals. Exploiting adsorption and
elution approaches, along with selected RBC testing
strategies, they uncovered many of the details
concerning the specificity and complexity of the Rh
blood group system. For example, the prediction that
Rh antigens are encoded by two genes, not one or
three, was adeptly forecast by Patricia Tippett based
solely on serologic observations.1 Many investigators
contributed to knowledge of the variability of the D
antigen2–6 and variants of the e antigen were elucidated
by Issitt7 and others.6,8,9 That work is the foundation of
our understanding today, as the new genetic
information builds upon the serologic footing.
Serologic reactivity is the basis for blood groups
important in blood transfusion practice because
serology defines an antigen. That fact will not change
as we use different testing methods in the future,
including those that are DNA based. The suggestion
that agglutination of RBCs is still the mainstay of blood
bank technology because the field is reticent to change
and stuck in the early 1900s is shortsighted; without a
serologic relationship,a variation in a blood group gene
at the DNA level is just another single nucleotide
polymorphism (SNP) that occurs once in every 100 to
300 bp in the human genome.10 These polymorphisms
are of only academic interest until associated with a
phenotype and found to be relevant to transfusion
medicine, by stimulation of an antibody, or to RBC
function, as when they result in a null phenotype.
Rh Background
Two genes (RHD, RHCE) located on chromosome
1p34–p3611 encode the Rh proteins designated RhD and
RhCE;one carries the D antigen and the other carries CE
antigens in various combinations (ce, Ce, cE, or CE).12–15
The genes are 97 percent identical and each has 10
exons, but they encode proteins that differ by 32 to 35
of 416 amino acids (shown as circles on the RhD protein
in Figure 1). Both proteins are predicted to cross the
membrane 12 times. On the RhCE protein, the E and e
antigens differ by one amino acid, Pro226Ala, located on
the fourth extracellular loop (Fig. 1). However, the
requirement for e antigen expression is more complex
than the 226Ala polymorphism and expression can be
altered by changes in other regions of the protein. These
changes are often encountered in people of African or
mixed ancestry6,16 and are responsible for weak or
altered e expression. C and c antigens differ by four
amino acids but only the amino acid change at position
Ser103Pro is predicted to be extracellular (Fig. 1).
Additionally, three of the polymorphic amino acids in
RhC are identical to RhD and explain the expression of
G antigen on both proteins.
Why is the Rh System So Complex?
The majority of blood group systems are encoded
by single gene loci. In contrast, the Rh system is
encoded by two genes that have many identical regions
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and the fact that they are in very close proximity on the
same chromosome affords the opportunity for
numerous exchange events between them. This results
in new hybrid proteins that carry portions of RhD and
portions of RhCE or vice versa. Most of these
exchanges occur by a process called gene conversion.
In this process, one member acts as donor template
during replication of the other but, unlike in
homologous recombination, the donor template
remains unaltered. The donated region can span
several base pairs, single exons,or even multiple exons.
These exchanges between RHD and RHCE generate
new polymorphic proteins and these hybrid proteins
are responsible for the myriad of antigens observed in
the Rh blood group system (reviewed in Westhoff17 and
Reid and Lomas-Francis18).
Why is D So Immunogenic?
Most blood group antigens differ from their
antithetical partners by a single amino acid change
(e.g., Jka/Jkb, Fya/Fyb, E/e, K/k, etc.). An important
consideration in the immunogenicity of an antigen is
the degree of foreignness to the host. RhD and RhCE
differ by 32 to 35 amino acids, which explains why
RhD,when seen by the immune system of a D– person,
often induces a very robust immune response.
Although only nine or ten of the changes are predicted
to be extracellular, changes located in the trans-
membrane and cytoplasmic regions can also affect the
topology of the protein in the membrane. Additionally,
the large number of amino acid differences explains
the numerous epitopes of the D antigen, estimated to
range from 9 to more than 30.19,20 Exposure to a foreign
protein carrying this large number of amino acid
changes results in the production of a polyclonal
immune response directed at many different parts of
the protein.
What Causes the Large Number of Variations
in Expression of D?
D negative
The RBCs of D– individuals lack RhD protein
because of deletion,21 or, rarely, a mutation, of the RHD
gene (Fig. 1). The D– phenotype is much more
prevalent in Caucasians of European descent
(15%–17%), less likely in individuals with African
backgrounds (3%–5%), and rare in Asian populations 
(< 0.1%).6 The D– phenotype has arisen numerous
times, as evidenced by the different genetic events
responsible for the D– phenotype in different
populations. In Caucasians, it is primarily the result of
deletion of the entire RHD gene.21 Some exceptions
exist, including RHD genes that are not expressed
because of a premature stop codon, nucleotide
insertions, point mutations, or RHD/CE hybrids.18,22
Because most of the exceptions arise on DCe (R1) or
DcE (R2) backgrounds and result in the less common
Ce (r′) or cE (r″) haplotypes, the presence of these
unusual haplotypes is a useful marker for these
exceptions.
In contrast to the complete RHD deletion found in
Caucasians, D– phenotypes in African and Asian
persons are often caused by inactive or silent RHD
genes. Only 3 to 7 percent of South African black
persons are D–, of which 66 percent have RHD genes
that contain a 37-bp internal duplication resulting in a
premature stop codon.23 The 37-bp insert RHD
pseudogene is also found in 24 percent of D– African
Americans. Additionally, 15 percent of the D–
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Fig. 1. Diagram of the RHD and RHCE gene locus (top) and of the Rh
proteins in the RBC membrane (bottom).
The two RH genes have opposite orientation, with the 3′ends
facing each other. SMP, a gene of unkown function, is located
between them. Most D– Caucasian individuals have a complete
deletion of RHD.
The RhD and RhCE proteins are predicted to have twelve
transmembrane domains. Amino acid positions that differ
between RhD and RhCE are shown as dark circles on RhD. The
locations of the C/c and E/e polymorphisms are shown on RhCE.
Rh-positive RHD SMP1 RHCE
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D antigen
phenotypes in Africans result from a hybrid RHD-CE-D
linked to ceS, termed (C) ceS, which is characterized by
expression of VS, altered C and e (which may appear
weakened), normal c, and no D antigen.16 The weak C
phenotype is only observed with polyclonal reagents;
monoclonal reagents are strongly reactive with (C) ceS
RBCs. The prevalence of this haplotype in sickle cell
patients can complicate transfusion because this C
antigen is altered and these patients may make anti-C
when stimulated. In D– African Americans, 54 percent
completely lack the RHD gene, while the remaining
have either the 37-bp insert RHD pseudogene or the
hybrid RHD-CE-D.23
Asian D– phenotypes result from mutations in RHD
most often associated with Ce, indicating that they
originated on a DCe (R1) haplotype. Many Asians
whose RBCs type as D– are actually Del.
24,25
Del
Del refers to RBCs with a very low level of D antigen
that is detectable only by adsorption and elution,hence
the name. Because these RBCs type as D– (including
testing by the IAT), they are often only recognized if
they stimulate production of anti-D in a D–
recipient.26,27 This very low level D expression results
from several different RHD mutations; currently there
are five confirmed DEL alleles.28 Because these are
different mutations, the RBCs can vary in the amount of
D antigen expressed and in the effect on D epitope
expression. Those resulting from mutations in the
intron 3 splice site (designated IVS3+1g>a) have
altered D epitopes, as evidenced by epitope mapping
and by the production of anti-D after emergency
transfusion of D+ units. This mutation appears to cause
a partial Del phenotype.
28 Although investigation of the
other four Del backgrounds did not show epitope
alteration,28 this is not definitive because testing is
limited by available reagents and not all D epitopes are
known.
Del RBCs are most often found in Asians, with the
most frequent mutation being a 1227G>A change with
skipping of exon 9.25 However, a DEL allele encoding
a M295I amino acid change,which has the highest level
of D antigen expression,28 has been found in 1 in 3700
Europeans.22 The observation that Del phenotypes may
be infrequent, but not rare, along with two recent
reports of donor RBCs with a Del phenotype that
stimulated anti-D in D– recipients,26,27 have motivated
discussions suggesting that these might be an emerging
problem.29 Some have suggested consideration of
removing Del RBCs from the D– donor pool by
implementation of DNA-based testing methods.30
Importantly, since all Del samples reported to date
express the C antigen and appear to be r′, the D– C+
phenotype is a useful marker for samples that
potentially could be Del.
Weak D (formerly Du)
Weak D RBCs are historically defined as having
reduced D antigen levels that require the IAT for
detection. An estimated 0.2 to 1 percent of Caucasians
have RBCs with weak D expression,6 but the number of
samples classified as weak D can depend on the
characteristics of the typing reagent. Weak D RBCs
were thought to simply have a reduction in the level of
D antigen (i.e., a quantitative rather than a qualitative
difference), based on the observation that individuals
with weak D RBCs generally did not make anti-D when
transfused with D+ RBCs.31 From the work of Wagner
et al.,32 it is clear that the majority of weak D pheno-
types have at least one amino acid change in RhD.
Fig. 2. Diagram of amino acid changes in RhD proteins. The location is
shown as dark circles.
A. Weak D phenotypes. Amino acid changes that cause weak D
expression are predicted to be located predominantly in
transmembrane and cytoplasmic regions. B. Partial D
phenotypes. Amino acid changes that cause partial D phenotyes
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Because the changes are intracellular or are in the
transmembrane regions of RhD and not on the outer
surface of the RBC (Fig. 2A), these RBCs do not lack
extracellular D epitopes.32 They affect primarily the
efficiency of insertion and, therefore, the quantity of
RhD in the membrane. This is reflected in the reduced
number of antigen sites on these RBCs and explains
why the IAT is required for detection. Weak D
expression is caused by a large number of different
mutations (classified as Types 1 to 4233), with the most
common being a Val270Gly substitution designated
Type 1.32 The majority of individuals with weak D
phenotypes can safely receive D+ RBCs and will not
make anti-D. Nevertheless, because amino acid
changes located intracellularly or in the
transmembrane regions have the potential to alter
surface epitopes, it is still unclear which of the 42
different weak D types may have altered D epitopes.
Indeed, individuals with weak D type 4.2 and 15 have
been reported to make anti-D.34 Therefore, they are
better classified as partial D.17
Partial D (D categories or D mosaics)
RBCs with partial D antigens have historically been
classified as such because the RBCs type as strongly D+
but the individuals make anti-D when exposed to
normal D antigen. It was hypothesized that the RBCs
of these individuals lack some part of RhD so that they
can produce antibodies to the missing portion.
Molecular analysis has shown that this hypothesis was
correct and that the altered or missing portions of RHD
are actually replaced by corresponding portions of
RHCE. Some replacements involve single amino acids
but, in contrast to weak D discussed above, these
changes are predicted to be located in the extracellular
loop regions of RhD (Fig. 2B). Others involve entire
exons or large regions of the gene and the novel
sequence of amino acids generates new antigens (e.g.,
DW, BARC, Rh32) (reviewed in Westhoff17 and Reid and
Lomas-Francis18). Individuals with partial D antigens
can make anti-D and, ideally, should receive D– donor
RBCs. In practice, however, most are typed as D+ and
are only recognized after the individual makes anti-D.
D epitopes expressed on Rhce proteins (DHAR, ceCF,
ceRT) 
The discovery that some Rhce proteins carry D-
specific amino acids that react with some monoclonal
anti-D reagents adds an additional layer of complexity
to D typing. Two examples, DHAR (R0
Har),35,36 found in
individuals of German ancestry, and Crawford (ceCF),
found in individuals of African ancestry, deserve
attention because of their strong reactivity (3+–4+)
with some FDA-licensed monoclonal reagents and lack
of reactivity with others (including the weak D test)
(Table 1).
DHAR RBCs can be characterized serologically by
their strong reactivity with monoclonal anti-D clones
GAMA401 (present in Gamma-clone) and MS201
(present in Immucor Series 4 and Ortho Gel) while
showing no reactivity with MAD2 (present in Ortho
tube) or with polyclonal reagents (including the weak
D test). They can also react variably with Th28
(Immucor Series 5). These individuals do not have a
RHD gene,but exon 5 of their RHCE gene is from RHD
(Fig. 3). They can make anti-D when stimulated35 and
should be treated as D– for transfusion and Rh immune
globulin prophylaxis and as D+ as donors.
Crawford (Rh43) is found in persons of African
heritage and was first described in 1980.37 The antigen
was present on the RBCs of 1 in 950 random African
Americans in the southeastern part of the United States.
Most Crawford+ samples were from persons with an r′S
haplotype, but exceptions were seen. The Crawford
allele, ceCF, encodes the same amino acid changes
found in ceS (W16C, L245V) but also carries an
additional Q233E change, which is a D-specific residue
on the ceS background.38,39 The D-specific residue
(233E) is responsible for strong direct agglutination
(3+) with the GAMA401 clone but it does not react with
Table 1. Reactivity of FDA-licensed anti-D reagents with some Rh variant RBCs that resulted in D typing discrepancies  
IgM DVI DHAR Crawford Choice of 
Reagent monoclonal IgG IS/AHG DBT (Caucasian) (Blacks) reagent for
Gamma-clone GAMA401 F8D8 monoclonal Neg/Pos* Pos Pos Pos DONORS
Immucor Series 4 MS201 MS26 monoclonal Neg/Pos Pos Pos Neg –
Immucor Series 5 Th28 MS26 monoclonal Neg/Pos Pos Vary/Pos Neg –
Ortho BioClone MAD2 Polyclonal Neg/Pos Neg/Pos Neg/Neg Neg RECIPIENTS (No IAT)
Ortho Gel (ID-MTS) MS201 – Neg Pos Pos Neg –
Polyclonal – – Neg/Pos Neg/Pos Neg/Neg Neg/Neg –
*Result following slash denotes anti-D test result by the IAT, as permitted by the manufacturer.
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D antigen
the anti-D present in Ortho, Immucor, and polyclonal
reagents (Table 1). These individuals make anti-D when
stimulated (our unpublished observations) and should
be treated as D– for transfusion and Rh immune
globulin prophylaxis. Although Crawford+ RBCs have
not yet been reported to stimulate production of anti-D,
most would agree that individuals with this phenotype
are better classified as D+ as donors.
Lastly, a Rhce protein with a R154T mutation,
designated ceRT, demonstrates weak reactivity with
some anti-D monoclonal reagents, and the reactivity is
enhanced at lower temperatures. Interestingly, this
variant does not carry any D-specific amino acid but
mimics a D-epitope (epD6) structure.40
D Typing Discrepancies
Multiple factors conspire to complicate D typing in
the United States. These include the numerous methods
used (i.e., slide, tube, solid phase, gel, and automated
analyzers using enzyme-treated RBCs) as well as
variations in the phases of testing;dissimilar monoclonal
antibodies present in manufacturers’ FDA-licensed
reagents that can differ in reactivity with variant D
antigens; and the large number of different RHD genes
present in populations, which affects both the level of
expression and,potentially, the structure and epitopes of
the D antigen. To date, there are more than 100 different
RHD genes known, including 42 that encode different
forms of weak D,40 that result in expression of different
partial D antigens, 5 or 6 DEL, and several RHCE genes
that encode D epitopes on the Rhce protein. If one
takes into account differences in methods, antibody
clones, and the variability of D expression,discrepancies
are bound to occur and the surprise should probably be
that they are not encountered more often.
Methods
Multiple methods for D typing are used in various
facilities in the United States. A 2001 to 2004 College
of American Pathologists’ (CAP) survey of North
American D Testing Practices41 showed an increase in
the use of gel technology (1.1%–7.7%) but multiple
methods will continue to be used. Regarding weak D,
although testing is the standard practice for donor D
determination, there are wide variations in practices in
hospital transfusion services. Data from a 1999 CAP
survey42 revealed that weak D testing was performed in
58 percent of responding facilities, although that
number has likely dropped since then. A striking
feature of the survey was the absence of a standard of
practice regarding the D phenotype of units transfused
to recipients testing positive for weak D. Forty-four
percent indicated that they would give D– RBCs, while
42 percent would give D+ RBCs. About 10 percent
would give D– donor RBCs if the woman was of
childbearing age. These statistics may reflect
uncertainty regarding the significance of weak D and
also the conservation and limited availability of D–
donor units.
Reagents
Early reagents developed for D antigen testing
exploited antibodies produced in D-sensitized women
or hyperimmunized volunteers. These polyclonal
antibodies were potent and effective because they
recognized numerous epitopes of D. Some were IgM
antibodies causing direct agglutination but most were
IgG. IgG antibodies are unable to cross-link D antigens
on adjacent RBCs and cause direct agglutination,
probably because of the number of sites and the lack of
mobility of the protein. IgG reagents were often
subjected to either chemical modification or addition
of potentiating agents, with the goal of enhancing
cross-linking to produce direct agglutination.
With the advent of monoclonal antibody
technology in the 1980s came the promise of freedom
from reliance on human source material for anti-D. The
fusion of specific antibody-producing B cells with
immortalized cell lines allows production of antibodies
in cell culture and a potentially inexhaustible source. A
large number of IgM, direct-agglutinating, anti-D
monoclonals were generated, although it was soon
realized that a single monoclonal anti-D specific for a
single D epitope did not detect all D+ RBCs. Therefore,
D typing reagents in the United States are a blend of
monoclonal IgM reactive at room temperature and
monoclonal or polyclonal IgG reactive by the IAT for
the determination of weak D. The U.S. market offers
four different reagents for tube testing and one for gel
(Table 1). All but two contain different IgM clones, so
Fig. 3. Diagram of the RHCE genes that encode proteins reactive with
some D typing reagents. The ten exons are represented by grey
boxes, and the RHD-specific exon 5, or D-specific residues
(position 223 and 245) are shown.
No RHD DHAR
RHCE
1 2 3 4 5 6 7 8 9 10
No RHD ceCF
W16C Q223E L245V
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the reactivity of each with variant D antigens may
differ. The FDA requires only that manufacturers
specify reactivity with category DIV, DV, and DVI RBCs
and only limited studies have been carried out with
these U.S. reagents to characterize reactivity with other
D variants.43 Additional data are needed concerning
the reactivity of molecularly characterized variant D
antigens with FDA-licensed reagents. The RBCs used
for these studies must be well characterized at the
molecular level, as the same category D RBCs may have
different genetic backgrounds that can impact the data.
Table 1 compares the reactivity of different
manufacturers’ reagents with some of the more
frequently encountered RhD and RhCE variants that
cause D typing discrepancies referred to our laboratory
for investigation by molecular techniques. This serologic
information, along with knowledge of the ethnic
background of the donor or patient, can be very helpful
in resolving the discrepancy. Additionally, although this
comparison only includes four different variant D, it
suggests that the Gamma reagent used in the donor
setting would successfully exclude DVI, DBT, DHAR, and
Crawford phenotype RBCs from the D– donor pool by
typing them as D+. This comparison also suggests that
the Ortho tube reagent best serves these individuals in
the hospital or prenatal setting by classifying the RBCs as
D– for transfusion and Rh immune globulin purposes.
(Note the importance of eliminating the antihuman
globulin [AHG] testing phase on recipients to achieve
the desired interpretation for DVI and DBT.)  
The suggestion that there should be different anti-
D reagents used for donor D determination and for
typing patients is not new. This concept was avidly
debated in the United States in the early days of
implementation of monoclonal antibody reagents.44
Discussions primarily focused on category VI RBCs, the
most common D variant in Caucasians. Because DVI
RBCs can stimulate production of anti-D in a D–
individual, the reagent for typing donors should be
reactive with these RBCs. However, since these
individuals often make anti-D when exposed to
conventional D through transfusion or pregnancy, the
reagent for use in typing patients’ samples would be
selected to not react with category VI RBCs. At that
time,however, it was felt that this was not practical and
that being called D+ as a donor and D– as a patient was
problematic.44 Blends were judged to be the best
answer; this is reflected in the current reagents
available in the United States. In all of them, the IgM
anti-D component does not react with DVI RBCs but
the IgG component reacts with these RBCs in the AHG
phase of testing (Table 1). This has prompted the
movement away from weak D testing in the hospital
and prenatal setting to better serve individuals with
DVI RBCs by classifying them as D–. This movement
was slow to develop, however, and many hospital
transfusion service laboratories were still performing
the weak D test in the 1999 CAP survey,42 a decade
after implementation of monoclonal reagents.
Reporting Variable Reactivity With Anti-D
Typing Reagents
How does the laboratory report the D type when
testing results differ between various manufacturers’
reagents or between transfusion service and donor
center D typing?  Key to assigning D antigen status
should be whether the patient is a blood donor or a
transfusion recipient. DNA-based testing is very useful to
confirm the molecular basis underlying D typing
discrepancies, but is not always necessary if a thorough
serologic workup is performed. Most agree that
serologically or molecularly confirmed D variants should
be considered D+ as blood donors but D– as recipients.
Historically it has caused consternation within the
profession to label an individual as D+ in one situation
and D– in another. Laboratories fear appearing indecisive
and do not want to confuse the patient or donor, the
physician, or the nursing staff. However, as we move
toward an age of well-informed medical care consumers,
with the promise of designer health care algorithms and
treatments based on genetic polymorphisms, any RHD
polymorphism that results in altered D antigen
expression is relevant and should be part of the medical
record. To begin to move in this direction,one colleague
has modified the acceptable Rh typing interpretation
fields in the hospital computer system to include POS,
NEG, and DEP. DEP is translated to “Negative*” in this
hospital setting, with the following explanatory remark.
“*The Rh type is dependent on reagents used, tests
performed, and/or technical performance. Patient may
have been previously reported as Rh Positive or Rh
Negative. For Transfusion Service testing, the patient
will be treated as Rh Negative, a candidate for Rh
Immune Globulin, and will receive Rh Negative blood.
As a Blood Donor, patient will be treated as Rh
Positive.”* (B. Sipherd, personal communication, 2005) 
European D Testing
In Europe, weak D testing is not performed; two
different IgM monoclonal anti-D reagents are used for
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initial D typing. For testing recipients, at least one must
not react with category DVI RBCs, so that these
individuals are properly classified as D– for transfusion
and Rh immune globulin prophylaxis. Many more
monoclonal anti-D reagents are available in Europe and
most do not use the same clones that are licensed in
the United States. The wider availability of
monoclonals and the fact that a weak D test is not
performed are important considerations when
reviewing data from recent European publications
detailing the frequency of D+ donors not detected by
routine testing. One cannot directly extrapolate to the
incidence in the United States when the anti-D clones
and methods differ.
D Typing Concerns
Issues of concern for the determination of the D
status of donors differ from those for transfusion
recipients. In donors, the issue is one of detection of
any and all D antigen expression. In recipients, it is one
of detection of D antigens with altered D epitopes.
Donors
Ideally, tests to determine a donor’s D status would
detect all RBCs with any amount of D antigen or D
epitope expression as D+. Unfortunately, some RBCs
with the weak D phenotype may be “missed”
serologically, and there are no serologic reagents to
detect Del RBCs. It had been suggested that the number
of antigen sites, termed the Rhesus index, might be a
way to distinguish which RBCs would be immunogenic
when transfused to D– recipients, with a possible
cutoff of 300 to 400 antigen sites required.45 Antigen
dose is one consideration that determines
immunogenicity, but the large number of RBCs
associated with a unit of blood will compensate for a
low number of antigen sites. RBCs with less than
approximately 30 sites stimulate anti-D.27,28 Molecular
screening for the presence of the RHD gene would
detect these and testing could be done as pools,31
lending support for future implementation of DNA
testing methods in donor centers. However, the
absolute association of the C phenotype with the DEL
alleles described to date, as well as the strong
association of either C or E phenotypes with weak D
types that might not be detected serologically, suggest
that elimination of apparent r′ (D– C+) or r″ (D– E+)
donors from the D– donor pool would be an effective
approach for those concerned about screening out
donor units capable of immunizing D– recipients.
Alternatively, molecular testing could target specifically
this group of D– donors to test for the presence of the
RHD gene. Indeed, molecular screening for the
presence of RHD in D– donors who phenotype as D–
and C+ or E+ has been implemented in some Central
European blood centers.46
Patients
Ideally, tests to determine a patient’s D status would
distinguish those with RBCs that lack, or have altered,
D epitopes (and are at risk of immunization to
conventional D) from those that carry mutations that
simply reduce expression levels of D (and do not
confer such risk). Unfortunately, standard serologic
anti-D reagents cannot discriminate partial D RBCs.Nor
can they identify weak D RBCs that, similar to Type 4.2
and Type 15,34 have altered D epitopes manifest as
production of anti-D when transfused with
conventional D+ RBCs. On a positive note, our long
history of transfusing patients who have weak D RBCs
with conventional D+ donor blood strongly suggests
that weak D Types 1, 2, and 3, which comprise at least
90 percent of weak D individuals, do not make anti-D,
as others have emphasized.30 It is also important to put
the “D dilemma” into perspective. We routinely accept
that 10 percent of recipients are potentially exposed to
c and K antigens. Severe anemia and hemolytic disease
of the fetus and newborn have been reported due to
maternal anti-c or -K stimulated by transfusion. Most
believe that routine matching for c and K is not
justified even in females of childbearing age. Perhaps it
might be appropriate to revisit this policy;however, the
question is one of clinical allocation of resources.
Importantly, is D different, in that we will not tolerate
any anti-D immunizations?  
Will DNA-Based Testing Be the Answer for 
D Typing?
DNA-based testing strategies can, by sampling
multiple regions of the RH genes, determine a specific
weak D type or partial D category or the presence of
Del. Currently, this can be cumbersome, often requiring
complete gene sequencing. The development of
automated, high-throughput platforms that sample
many regions of both RHD and RHCE, along with
detailed algorithms for accurate interpretation, are
needed. The significance of many of the other weak D
types (Types 4–42) has not been determined because
serologic evidence, in the form of immunization and
production of antibodies in recipients, is not available.
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Because direct experimentation and deliberate
immunization cannot be used to answer the question
of which RBCs lack, or have altered, D and which
mutations simply reduce expression levels of D, it is
important to investigate D+ patients who make anti-D.
Although anti-D immunization is probably still
infrequent or rare, as pointed out previously,30 the
observation that 32 percent of participants in the 1999
CAP survey had observed at least one case per year of
a weak D individual who had anti-D and 21 percent had
encountered two or more cases might suggest
otherwise.42 To gather the appropriate information
relevant to the test methods and anti-D reagents used
in the United States, it will be important for
laboratories to investigate the following:
1. D– patients who receive D– products but
produce anti-D.
2. Products labeled D– that may have stimulated
anti-D.
3. D+ patients who make anti-D.
This should ideally include serologic workups
combined with molecular DNA testing. It is the
powerful combination of serology with genetics that
will define our future as we move into the postgenomic
era of DNA-based testing methods.
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